Related Experiment Video

Updated: Jun 14, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Role of Radiation-induced TGF-beta Signaling in Cancer Therapy

Horatiu C Dancea1, Mohammed M Shareef, Mansoor M Ahmed

  • 1Department of General Surgery, Geisinger Clinic, Danville, Pennsylvania.

Molecular and Cellular Pharmacology
|September 28, 2011
PubMed

Insights

Transforming growth factor-beta (TGF-β) signaling impacts cancer and development. Neutralizing TGF-β shows promise in overcoming radioresistance and developing new radio-therapeutic strategies for solid tumors.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Transforming growth factor-beta (TGF-β) signaling is crucial for cell growth, differentiation, apoptosis, motility, angiogenesis, epithelial-mesenchymal transition, and extracellular matrix production.
  • TGF-β's role in embryonic development and disease pathogenesis, including cancer, is context-dependent, sometimes promoting and sometimes suppressing cell growth and invasion.
  • Dysregulation of TGF-β signaling, through mutations in TGF-beta type II receptor (TβRII) or Smad4, contributes to cancer progression and loss of growth suppression.

Purpose of the Study:

  • To investigate the multifaceted roles of TGF-β signaling in biological processes and cancer.
  • To explore the potential of targeting TGF-β signaling in radio-adjuvant therapies.
  • To understand the mechanisms underlying TGF-β's involvement in radiation-induced normal tissue injury and fibrosis.

Main Methods:

  • Utilized classical TGF-β pathway components like TβRII and SMAD4 in radio-adjuvant therapy studies.
  • Investigated the negative feedback mechanism involving SMAD7 in radiation-induced TGF-β signaling.
  • Employed neutralizing antibodies against TGF-β to assess radioresistance effects.

Main Results:

  • TGF-β signaling can promote cell proliferation and invasion in certain contexts, despite its known growth-inhibitory effects.
  • Radiation induces TGF-β, primarily contributing to normal tissue injury and fibrosis.
  • Neutralizing antibodies against TGF-β demonstrated a robust radio-resistant effect in studies.

Conclusions:

  • Understanding TGF-β signaling interactions is key to developing effective adjuvant radio-therapeutic strategies for solid tumors.
  • Targeting TGF-β, particularly through antibody neutralization, offers a promising approach to enhance radio-therapeutic efficacy and mitigate radioresistance.
  • Further research into the functional interactions of TGF-β pathway components may lead to improved cancer treatment protocols.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...